Safety and Efficacy of Mepolizumab in Hypereosinophilic Syndrome: An Open-Label Extension Study

202142 citationsJournal Articlehybrid Open Access

Authors

Gerald J. Gleich · University of Utah

Florence Roufosse · Erasmus Hospital

Geoffrey Chupp · Yale University

Stanislas Faguer · Centre Hospitalier Universitaire de Toulouse

Bastian Walz · University of Tübingen

Andreas Reiter · Heidelberg University

Steven W. Yancey ·

Abstract

Extended mepolizumab treatment was associated with a positive benefit-risk profile. Continued control of disease flares and blood eosinophil counts, plus reductions in OCS use, were observed with mepolizumab in patients with FIP1-like-1-platelet-derived growth factor receptor α-negative HES.

Topics & Keywords

Eosinophilic Disorders and Syndromes Eosinophilic Esophagitis Urticaria and Related Conditions

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: The Journal of Allergy and Clinical Immunology In Practice

Volume 9, Issue 12, pp. 4431-4440.e1

DOI: 10.1016/j.jaip.2021.07.050

Field-Weighted Citation Impact: 5.10